These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

496 related articles for article (PubMed ID: 26260691)

  • 1. Clinical differences between botulinum neurotoxin type A and B.
    Bentivoglio AR; Del Grande A; Petracca M; Ialongo T; Ricciardi L
    Toxicon; 2015 Dec; 107(Pt A):77-84. PubMed ID: 26260691
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evidence-based review and assessment of botulinum neurotoxin for the treatment of movement disorders.
    Hallett M; Albanese A; Dressler D; Segal KR; Simpson DM; Truong D; Jankovic J
    Toxicon; 2013 Jun; 67():94-114. PubMed ID: 23380701
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evidence-based review and assessment of botulinum neurotoxin for the treatment of secretory disorders.
    Naumann M; Dressler D; Hallett M; Jankovic J; Schiavo G; Segal KR; Truong D
    Toxicon; 2013 Jun; 67():141-52. PubMed ID: 23178324
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evidence-based review and assessment of botulinum neurotoxin for the treatment of urologic conditions.
    Chancellor MB; Elovic E; Esquenazi A; Naumann M; Segal KR; Schiavo G; Smith CP; Ward AB
    Toxicon; 2013 Jun; 67():129-40. PubMed ID: 23415704
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evidence-based review and assessment of botulinum neurotoxin for the treatment of adult spasticity in the upper motor neuron syndrome.
    Esquenazi A; Albanese A; Chancellor MB; Elovic E; Segal KR; Simpson DM; Smith CP; Ward AB
    Toxicon; 2013 Jun; 67():115-28. PubMed ID: 23220492
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Abo-, inco-, ona-, and rima-botulinum toxins in clinical therapy: a primer.
    Chen JJ; Dashtipour K
    Pharmacotherapy; 2013 Mar; 33(3):304-18. PubMed ID: 23400888
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of long-term botulinum toxin treatment for acquired cervical dystonia: a 25-year follow-up.
    Petracca M; Lo Monaco MR; Ialongo T; Di Stasio E; Cerbarano ML; Maggi L; De Biase A; Di Lazzaro G; Calabresi P; Bentivoglio AR
    J Neurol; 2023 Jan; 270(1):340-347. PubMed ID: 36068376
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Use of botulinum neurotoxin therapy].
    Mukai Y; Kaji R
    Brain Nerve; 2011 Jul; 63(7):775-84. PubMed ID: 21747148
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A pharmacodynamic comparison study of different botulinum toxin type A preparations.
    Kim SB; Ban B; Jung KS; Yang GH
    Dermatol Surg; 2013 Jan; 39(1 Pt 2):150-4. PubMed ID: 23301818
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Conversion Ratio between Botox®, Dysport®, and Xeomin® in Clinical Practice.
    Scaglione F
    Toxins (Basel); 2016 Mar; 8(3):. PubMed ID: 26959061
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hyperhidrosis: anatomy, pathophysiology and treatment with emphasis on the role of botulinum toxins.
    Lakraj AA; Moghimi N; Jabbari B
    Toxins (Basel); 2013 Apr; 5(4):821-40. PubMed ID: 23612753
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The rat Digit Abduction Score (DAS) assay: a physiological model for assessing botulinum neurotoxin-induced skeletal muscle paralysis.
    Broide RS; Rubino J; Nicholson GS; Ardila MC; Brown MS; Aoki KR; Francis J
    Toxicon; 2013 Sep; 71():18-24. PubMed ID: 23707612
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transient Improvement after Switch to Low Doses of RimabotulinumtoxinB in Patients Resistant to AbobotulinumtoxinA.
    Hefter H; Samadzadeh S; Moll M
    Toxins (Basel); 2020 Oct; 12(11):. PubMed ID: 33121133
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Mechanism of therapy effects by botulinum neurotoxin].
    Alajbegović A; Alajbegović S; Resić H
    Med Arh; 2008; 62(1):53-5. PubMed ID: 18543757
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Botulinum toxin type B vs. type A in toxin-naïve patients with cervical dystonia: Randomized, double-blind, noninferiority trial.
    Pappert EJ; Germanson T;
    Mov Disord; 2008 Mar; 23(4):510-7. PubMed ID: 18098274
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Botulinum toxin type-A preparations are not the same medications - clinical studies (Part 2).
    Sławek J; Bogucki A; Bonikowski M; Car H; Dec-Ćwiek M; Drużdż A; Koziorowski D; Sarzyńska-Długosz I; Rudzińska M
    Neurol Neurochir Pol; 2021; 55(2):141-157. PubMed ID: 33797748
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity and long-term efficacy of botulinum toxin type B in the treatment of cervical dystonia: report of 4 prospective, multicenter trials.
    Chinnapongse RB; Lew MF; Ferreira JJ; Gullo KL; Nemeth PR; Zhang Y
    Clin Neuropharmacol; 2012; 35(5):215-23. PubMed ID: 22932474
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A new treatment for focal dystonias: incobotulinumtoxinA (Xeomin®), a botulinum neurotoxin type A free from complexing proteins.
    Jimenez-Shahed J
    Neuropsychiatr Dis Treat; 2012; 8():13-25. PubMed ID: 22275842
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In-vivo comparison of the neurotoxic potencies of incobotulinumtoxinA, onabotulinumtoxinA, and abobotulinumtoxinA.
    Kutschenko A; Manig A; Reinert MC; Mönnich A; Liebetanz D
    Neurosci Lett; 2016 Aug; 627():216-21. PubMed ID: 27268041
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Botulinum toxins in the treatment of primary focal dystonias.
    Truong D
    J Neurol Sci; 2012 May; 316(1-2):9-14. PubMed ID: 22336699
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.